Top Biotech Companies in Boston, MA (391)
At OPKO Health, we seek to serve unmet patient needs through our first in class products, comprehensive diagnostics laboratories, robust research and development pipeline, and unique pharmaceutical business solutions. The entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs. We are proud...
Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of...
BioLabs are the premier co-working spaces for life science startups, unique places for test, develop & grow your game-changing ideas.
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely...
Endpoint Clinical, Inc.'s Top Stability & Growth Strengths
Strong Market Position & Advantage: The company is repeatedly characterized as a global leader in RTSM/IRT with substantial operating scale, supporting 2,000+ studies across 90+ countries and 800+ active studies. This breadth and ability to handle complex, global trials provide a durable competitive edge.
Investor Backing & Capital Strength: The June 2024 acquisition by Arsenal Capital Partners supplies focused capital and sponsor support to accelerate expansion and innovation. This backing is presented as validation of market position and a catalyst for the next phase of growth.
Innovation-Driven Growth: Five generations of purpose-built RTSM platforms and the proprietary PULSE platform, including faster study builds in four weeks or less, indicate sustained product advancement. A 2025 brand refresh and continued tech investment underscore a roadmap aimed at pushing RTSM forward.
Genialis is a computational precision medicines company unravelling complex biology to find new ways to address disease. ResponderID™, Genialis’ clinical biomarker discovery platform, defines, models, and validates actionable biomarkers and optimally positions novel drugs to accelerate translational research and clinical development. Genialis is trusted by biopharma and big pharma alike, and together, we bring precision to medicine.
Cullinan Oncology is dedicated to creating new standards of care for patients with cancer. We innovate without borders to find the most promising clinic-ready cancer therapies, whether from our own discovery efforts or through exceptional engagement with our academic and industry partners. Anchored in a deep understanding of immuno-oncology and translational cancer medicine, we leverage our scientific excellence in small molecules and...
Maven Bio keeps the documents behind biopharma decisions current as the industry changes. Teams use Maven to build and maintain competitive views, asset screens, portfolio briefs, and target product profile benchmarks. They define the assets, markets, and questions they care about. Maven monitors new evidence against those priorities, delivers relevant signals, and updates their documents, with sources attached and the option...
Kernal Biologics is a biotechnology company developing mRNA therapies that instruct specific cells to produce their own medicine, targeting diseases such as cancer and autoimmune disorders.
At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but difficult-to-drug targets. Others are building towards a future transformation of the drug development process … for Ventus, that future is already here. Our ReSOLVE™ platform integrates cutting-edge, structurally enabled, computational tools to identify and perfect new drug molecules for targets which have never been drugged...
Evolved By Nature is a new type of biotech company creating new molecules for a healthier future. With a belief that the next generation of products will advance the health of people and planet, we're using our sustainable molecule platform, Activated Silk™ technology, to create biomolecules, sustainable chemicals and natural ingredients that will increase the performance and decrease the environmental...
Lyra Therapeutics is a clinical-stage biotechnology company developing long-acting, locally delivered anti-inflammatory implants to treat chronic rhinosinusitis (CRS). The company designs bioabsorbable drug-eluting matrices that release steroid therapy directly to sinonasal tissues for sustained relief, advancing lead candidates (LYR-210 and LYR-220) through late-stage clinical trials and pursuing commercialization and strategic alternatives to benefit CRS patients.
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing...
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For...
Valerion Therapeutics is an emerging science-driven company focused on the development of bio-therapeutics for orphan genetic diseases. Valerion utilizes a proprietary cell-penetrating antibody to target the cytoplasm of affected tissues - a cell compartment previously out of reach for protein-based therapies. Our versatile platform can be conjugated to proteins, small molecules & oligonucleotides providing a novel pathway to treat previously...
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
CELLINK is proud to be a part of BICO, the world’s leading bioconvergence company. By releasing the first universal bioink in 2016, CELLINK democratized the cost of entry for researchers around the world and played a major role in turning the then up-and-coming field of 3D bioprinting into a thriving $1 billion industry. The company’s best-in-class bioinks, bioprinters, software and...
CELLINK's Top Stability & Growth Strengths
Strong Market Position & Advantage: CELLINK is widely characterized as a leader in 3D bioprinting, with broad adoption across thousands of academic and pharma labs and frequent inclusion among top players in industry overviews. Its end-to-end portfolio of extrusion and light-based bioprinters, bioinks, and software underpins this position.
Innovation-Driven Growth: Early category-defining moves (such as launching the first universal bioink) and continued expansion into advanced systems like BIO X/BIO X6, LUMEN X, and BIONOVA X highlight a sustained innovation engine. Acquisitions such as Allegro 3D broadened modalities and reinforced an integrated workflow approach.
Resilient & Sustainable Growth: Parent disclosures indicate a return to organic growth in early 2026 and note that turnarounds including CELLINK strengthened results after a choppy 2025. Segment commentary around Life Science Solutions (which includes CELLINK) points to stabilization despite soft academic end-markets.
The Institute for Protein Innovation is pioneering a new approach to scientific discovery and collaboration. As a nonprofit, we provide the biomedical research community with synthetic antibodies & deep protein expertise, empowering researchers to unlock the most elusive mysteries of biology. For more information, visit our website & follow us on Twitter & Instagram @ipiproteins
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology...































